Physician profile
Jonathan A Harris
NPI 1376563551
$2,008.39
in general payments reported to CMS, 2019-2025
30 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $193 · 2021: $143 · 2022: $478 · 2023: $341 · 2024: $240 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $363.72 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $359.98 | 2021-2025 | |
| Allergan, INC. | $146.24 | 2020 | |
| Pfizer INC. | $123.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $99.19 | 2020-2025 | Arexvy |
| Lilly USA, LLC | $97.08 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $89.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $79.79 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $71.20 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $69.64 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $65.23 | 2021-2022 | |
| Edwards Lifesciences Corporation | $46.21 | 2025 | |
| Corium, LLC | $45.66 | 2023 | Azstarys |
| Corcept Therapeutics | $31.59 | 2023 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $30.88 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.62 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.24 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $25.51 | 2019 | |
| Astellas Pharma US INC | $24.78 | 2023 | Veozah |
| Nevro Corp. | $23.66 | 2019 | |
| Verona Pharma, INC. | $22.25 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $18.94 | 2023 | Farxiga |
| Neurocrine Biosciences, INC. | $18.18 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $17.00 | 2023 | Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.19 | 2021 | |
| Si-Bone, INC. | $14.27 | 2019 | |
| Merck Sharp & Dohme LLC | $11.31 | 2019 | |
| Radius Health, INC. | $10.91 | 2019 | |
| Neuronetics, INC. | $10.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.